The beginning of the end of warfarin?

John W Eikelboom and Graeme J Hankey
Med J Aust 2004; 180 (11): . || doi: 10.5694/j.1326-5377.2004.tb06088.x
Published online: 7 June 2004

Randomised trials suggest that ximelagatran is “non-inferior” to warfarin for preventing stroke in patients with non-valvular atrial fibrillation, but important questions remain

  • John W Eikelboom1
  • Graeme J Hankey2

  • Royal Perth Hospital, Perth, WA.


Competing interests:

Graeme Hankey is a member of the Steering Committee of the AMADEUS trial, the Stroke Advisory Committee of the ACTIVE trial, and the Atrial Fibrillation Advisory Board for Exanta, AstraZeneca, Australia.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.